Novel intravesical therapies for non-muscle-invasive bladder cancer refractory to BCG

La Mont J. Barlow*, Catherine M. Seager, Mitchell C. Benson, James M. McKiernan

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations


The definitive treatment for patients with non-muscle-invasive bladder cancer (NMIBC) who fail to respond to intravesical BCG is cystectomy. When a patient is deemed BCG-refractory and cannot or will not undergo cystectomy, alternative intravesical therapy may be the most effective way to minimize recurrence and progression. A number of immunotherapeutic and chemotherapeutic agents have been given intravesically over the years, and several recently and currently investigated novel agents appear to be particularly promising for the management of BCG-refractory NMIBC. The most effective treatments in the future will likely utilize targeted therapies based on the underlying genetic mutations associated with each individual diagnosis of NMIBC.

Original languageEnglish (US)
Pages (from-to)108-111
Number of pages4
JournalUrologic Oncology: Seminars and Original Investigations
Issue number1
StatePublished - Jan 2010


  • BCG-refractory
  • Bladder cancer
  • Cystectomy
  • Intravesical
  • Novel agents

ASJC Scopus subject areas

  • Urology
  • Oncology


Dive into the research topics of 'Novel intravesical therapies for non-muscle-invasive bladder cancer refractory to BCG'. Together they form a unique fingerprint.

Cite this